STAT

Opinion: San Francisco’s Mission Bay life science sector: pivoting with the times

While #MissionBay hasn't quite captured the magnitude of biotech and pharma players as has #KendallSquare in Cambridge, the growth of its life sciences industry will continue in a very Left…
An aerial shot of San Francisco

Twenty years ago, San Francisco’s Mission Bay was an industrial zone filled with shipyards and railroad tracks. It was sluggish by day and deserted by night. Today, it is a vibrant health and biotech hub that continues to evolve. A note to the media: Don’t box us in.

When my company, Bayer, relocated its California research and innovation teams to Mission Bay in 2010, the decision was

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks